



PRESS RELEASE

Nicholas Piramal Secures Product Patent from US Patent & Trademark Office for its Cyclin-Dependent Kinase (CDK) inhibitors

Dr. Noopur Raje from Dana Faber Cancer Institute presenting on NPIL's lead compound P-276-00 at 49th American Society of Hematology Conference at Atlanta, USA

Mumbai, 10 December 2007: Nicholas Piramal India Limited (NPIL) announced today that the US Patent & Trademark office has granted Product Patent to NPIL. The granted claims of the patent cover the novel compounds, including NPIL's clinical candidate P-276-00, and processes for their preparation. These compounds are being developed as therapeutic agents useful in the treatment of cancer.

Earlier NPIL has been granted a patent in South Africa for its CDK inhibitors. NPIL has related national phase applications in 14 other countries. The Company has filed five other patent applications covering different aspects of its CDK inhibitors.

Dr. Noopur Raje from Dr. Ken Anderson group from Dana Faber Cancer Institute is giving an oral presentation today at 49th Annual Meeting and Exposition of American Society of Hematology (ASH) being held at Atlanta, Georgia in U.S. from December 8-10, 2007. They have carried out independent studies on NPIL's lead compound P-276-00 in Multiple Myeloma and will be presenting new data on its pre-clinical studies.

The ASH Annual Meeting is the premier forum for physicians and researchers to hear the most up-to-date developments in Hematology. The event attracts over 16,000 Hematologists and other health-care professionals from 100 countries around the world.

Dr. (Mrs.) Swati Piramal, Director – Strategic Alliances & Communications, NPIL said, "The presentation of data on pre-clinical studies at annual conference of American Society of Hematology marks an important milestone for development of NPIL's Oncology compound."

For further information contact:
Vijay Sathye
Sagar Gokani
Nicholas Piramal India Limited
Contact: +91-22-3046 6412/3046 6474
investorrelations@nicholaspiramal.co.in

About Nicholas Piramal India Limited:

Nicholas Piramal India Limited ("NPIL") is one of India's largest pharmaceutical companies with a growth track record of above 30% CAGR since 1988. The Company is currently ranked 4th in the Indian market with a diverse product portfolio spanning nine therapeutic areas. NPIL's had consolidated Revenues of Rs. 24.7 billion in 2006-07. The Company has R&D capabilities in Custom Chemical Synthesis, Process Innovation, NDDS and Basic Research. It has world-class USFDA-approved formulations and API facilities without any 483s.

NPIL has a long track record of successful collaboration with innovator companies. Since 2003, the Company has made significant investments to become a global custom manufacturing organisation ("CMO") for large and medium-sized innovator companies. Nicholas Piramal has a global CMO footprint across North America, Europe & Asia, and is committed to respecting Intellectual Property.

NPIL is listed in India on the Bombay Stock Exchange and National Stock Exchange. For further information, please mail investorrelations@nicholaspiramal.co.in or visit www.nicholaspiramal.com
